Summary
Diphenylhydantoin (2 mg/kg) was infused intravenously in four uraemic patients and four healthy volunteers and its plasma concentration measured during and after the infusion. The plasma concentrations were considerably lower in the uraemic subjects and the apparent volume of distribution was higher. These observations could be explained by the lower plasma protein binding of diphenylhydantoin in the uraemics. The overall elimination rate constant β was greater (shorter half-life) in the uraemic patients. This difference could not be explained by reduced plasma protein binding, but it might be due to induction of diphenylhydantoin metabolism in the uraemic state. it is concluded that monitoring of the plasma levels of drugs in uraemic patients should be combined with determination of the extent to which the compounds are bound to plasma proteins.
Similar content being viewed by others
References
Odar-Cederlöf, I., Lunde, P., Sjöqvist, F.: Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet1970 II, 831–832
Reidenberg, M., Odar-Cederlöf, I., Bahr, von C., Borgå, O., Sjöqvist, F.: Protein binding of diphenylhydantoin and desmethylimipramin in plasma from patients with poor renal function. New Engl. J. Med.285, 264–267 (1971)
Berlin, A., Agurell, S., Borgå, O., Lund, L., Sjöqvist, F.: Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid — a comparison between a gas chromatographic and spectrophotometric method. Scand. J. clin. lab. Invest.29, 281–287 (1972)
Ehrnebo, M., Agurell, S., Jalling, B., Boréus, L.-O.: Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults. Europ. J. clin. Pharmacol.3, 189–193 (1971)
Wagner, J. G.: Pharmacokinetics. J. M. Richards Laboratory, Grosse Pointe Park, Mich. USA, 1969
Dixon, W. J., Massey, J.: Introduction to statistical analysis. New York: McGraw-Hill Book Co 1957
Gibaldi, M.: Effect of mode of administration on drug distribution in a two-compartment open system. J. Pharm. Sci.58, 327–331 (1969)
Unger, A. H., Sklaroff, H. J.: Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias. J. Amer. med. Ass.200, 159–160 (1967)
Editorial: Cardiac arrhythmias and sodium diphenylhydantoin — an appraisal. J. Amer. med. Ass.201, 142–143 (1967)
Arnold, K., Gerber, N.: The rate of decline of diphenylhydantoin in human plasma. Clin. Pharm. Ther.11, 121–134 (1970)
Gerber, N., Wagner, J. G.: Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. Res. Commun. Chem. Pathol. Pharmacol.3, 455–466 (1972)
Benet, L. Z., Ronfeld, R. A.: Volume terms in pharmacokinetics. J. Pharm. Sci.58, 639–641, (1969)
Suzuki, T., Saitoh, Y., Nishihara, K.: Kinetics of diphenylhydantoin disposition in man. Chem. Pharm. Bull.18 (2), 405–411 (1970)
Letteri, J. M., Mellk, H., Louis, S., Kutt, H., Durante, P., Glazko, A.: Diphenylhydantoin metabolism in uremia. New Engl. J. Med.285, 648–652 (1971)
Bigger, J. T., Schmidt, D. H., Kutt, H.: Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation38, 363–374 (1968)
Lasseter, K.: Treatment of arrhythmias: basic considerations. Med. Clin. N. Amer.55, 435–444 (1971)
Helfant, R. H., Scherlag, B. J., Dameto, A. N.: The electrophysiological properties of diphenylhydantoin sodium as compared to procaineamide on the normal and digitalis-intoxicated heart. Circulation36, 108–118 (1967)
Ekelund, L.-G., Moberg, A., Olsson, A. G., OrÖ, L.: Recent myocardial infarction and the conduction system. Brit. Heart J.,34, 774–780 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Odar-Cederlöf, I., Borgå, O. Kinetics of diphenylhydantoin in uraemic patients: Consequences of decreased plasma protein binding. Eur J Clin Pharmacol 7, 31–37 (1974). https://doi.org/10.1007/BF00614387
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00614387